$2.33
-0.05 (-2.10%)
Open$2.34
Previous Close$2.38
Day High$2.35
Day Low$2.32
52W High$3.24
52W Low$1.37
Volume—
Avg Volume195.0K
Market Cap224.51M
P/E Ratio6.44
EPS$0.36
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,894.0% upside
Current
$2.33
$2.33
Target
$46.46
$46.46
$33.82
$46.46 avg
$60.35
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 36.63M | 14.58M | 13.34M |
| Net Income | 36.14M | 2.88M | 3.22M |
| Profit Margin | -56.1% | 19.8% | 24.2% |
| EBITDA | 32.52M | 4.55M | 4.43M |
| Free Cash Flow | — | 4.06M | 3.77M |
| Rev Growth | — | -8.4% | -7.1% |
| Debt/Equity | — | 0.65 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |